ADVANCE研究:自膨胀生物瓣治疗重度主动脉瓣狭窄的5年临床与超声心动图结果
ADVANCE研究评估自膨胀生物瓣经导管主动脉瓣植入术(TAVI)在真实世界高危重度主动脉瓣狭窄患者中的安全性和有效性,纳入12国44中心1015例患者。5年随访时全因死亡率为50.7%(95%CI 46.7%-54.5%),主要卒中5.4%;配对患者平均主动脉瓣压差8.8±4.4 mmHg,有效瓣口面积1.7±0.4 cm²,中度主动脉瓣反流从12.8%降至8.0%。结论提示瓣膜耐久性持续良好,再干预和血流动力学瓣膜功能障碍率低。
要点
- 5年全因死亡率50.7%,主要卒中5.4%。
- 配对患者平均压差8.8±4.4 mmHg,有效瓣口面积1.7±0.4 cm²。
- VARC-2瓣膜功能障碍2.6%,30天后再干预1.2%。
核心结论
- 真实世界老年高危患者自膨胀生物瓣TAVI 5年瓣膜耐久性持续良好,再干预和血流动力学瓣膜功能障碍率低。
研究设计与样本
- 多中心前瞻性研究,纳入12国44中心1015例症状性重度主动脉瓣狭窄且外科高危患者,996例尝试TAVI。
- 平均年龄81岁,平均logistic EuroSCORE 19.3±12.3%,5年随访可用465例(46.7%)。
- 不良事件由独立临床事件委员会按VARC-1标准裁定。
主要发现
- 5年全因死亡率50.7%(95%CI 46.7%-54.5%),主要卒中5.4%。
- 配对患者平均主动脉瓣压差8.8±4.4 mmHg(n=198),有效瓣口面积1.7±0.4 cm²(n=123)。
- 配对患者中度主动脉瓣反流从12.8%降至8.0%(n=125)。
- 30天后有超声数据或再干预的860例中,22例(2.6%)符合VARC-2瓣膜功能障碍,10例(1.2%)30天后再干预。
临床怎么用
- 对于外科高危的重度主动脉瓣狭窄老年患者,自膨胀生物瓣TAVI可作为治疗选择,5年耐久性数据支持其应用。
局限性
- 5年随访仅覆盖465例(46.7%),存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The ADVANCE study was designed to evaluate the safety and effectiveness of transcatheter aortic valve implantation (TAVI) with a self-expanding bioprosthesis in real-world patients with symptomatic, severe aortic stenosis at high surgical risk for valve replacement. METHODS AND RESULTS: Study participants were enrolled from 44 experienced centres in 12 countries. Patient eligibility, treatment approach, and choice of anaesthesia were determined by the local Heart Team. The study was 100% monitored, and adverse events were adjudicated by an independent clinical events committee using Valve Academic Research Consortium (VARC-1) criteria. There were 1015 patients enrolled with 996 attempted TAVI procedures. Mean age was 81 years, and mean logistic EuroSCORE was 19.3 ± 12.3%. Five-year follow-up was available on 465 (46.7%) patients. At 5 years, the rate of all-cause mortality was 50.7% (95% confidence interval: 46.7%, 54.5%), and the rate of major stroke was 5.4%. Haemodynamic measures remained consistent for paired patients with a mean aortic valve gradient of 8.8 ± 4.4 mmHg (n = 198) and an effective orifice area of 1.7 ± 0.4 cm2 (n = 123). Aortic regurgitation (AR) decreased over time and among paired patients dropped from 12.8% to 8.0% moderate AR at 5 years (n = 125). Of the 860 patients with echocardiographic data or a reintervention after 30 days, there were 22 (2.6%) patients meeting the VARC-2 criteria for valve dysfunction and 10 (1.2%) patients with a reintervention >30 days. CONCLUSION: Five-year results in real-world, elderly, high-risk patients undergoing TAVI with a self-expanding bioprosthesis provided evidence for continued valve durability with low rates of reinterventions and haemodynamic valve dysfunction. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01074658.
引用
- Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. 2017. PMID: 28633375. doi:10.1093/eurheartj/ehx295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。